

---

## Acalabrutinib

产品编号: D51103

CAS: 1420477-60-6

分子式: C<sub>26</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>

纯度: ≥98%

InChi: InChI=1S/C<sub>26</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H<sub>2</sub>,1H<sub>3</sub>,(H<sub>2</sub>,27,29)(H,28,30,35)/t19-/m0/s1

InChi Key: WDENQIQYWYTPO-IBGZPJMESA-N

Smiles: CC#CC(=O)N1CCC[C@H]1C1=NC(C2C=CC(=CC=2)C(=O)NC2C=CC=CN=2)=C2C(N)=NC=CN12

外观: 固体粉末

作用通路: Btk

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.